MDxHealth SA (MDXH) Stock Analysis
Verdict: AVOID
Robust revenue growth and high gross margins are overshadowed by negative equity and a $95M debt burden, making this a high-risk recovery play.
Investment score: 38/100
Analysis as of
Is MDxHealth SA stock worth reviewing? AI model thesis
MDXH is a micro-cap turnaround story with strong product margins (64%) but a broken balance sheet. While revenue is growing, the negative equity position and debt load create a high probability of further dilution. The model avoids this until the equity position turns positive or debt is restructured.
7-factor investment score
- Valuation: 45/100 (weight 20%)
- Financial Health: 15/100 (weight 15%)
- Technical Momentum: 50/100 (weight 15%)
- Earnings Quality: 30/100 (weight 15%)
- Insider Sentiment: 40/100 (weight 10%)
- Analyst Consensus: 65/100 (weight 10%)
- Risk-Adjusted Return: 25/100 (weight 15%)
MDxHealth SA opportunities and risks
What speaks for MDXH
- Path to Positive EBITDA by 2026
What speaks against MDXH
- Balance Sheet Insolvency
Peers and competitors
Frequently asked questions about MDxHealth SA (MDXH)
Is MDXH stock a good investment?
The cached TradeMates AI model rates MDxHealth SA as AVOID with an investment score of 38/100. MDXH is a micro-cap turnaround story with strong product margins (64%) but a broken balance sheet. While revenue is growing, the negative equity position and debt load create a high probability of further dilution. The model avoids this until the equity position turns positive or debt is restructured. This is algorithmic model output, not personal investment advice.
Is MDXH stock a buy?
The TradeMates model verdict for MDXH is AVOID with an investment score of 38/100. Treat this as a model signal to review, not a personal buy recommendation.